Sponsors

Alzheimer’s disease: the importance of blood-based biomarkers

With new treatments for Alzheimer’s disease, early diagnosis is vital, and this is where detection of appropriate biomarkers is crucial. Pathology in Practice Science Editor Brian Nation looks at recent published work in this area.

Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings

Palmqvist S, Whitson HE, Allen LA et al. Alzheimers Dement. 2025 Jul; 21 (7): e70535. doi: 10.1002/alz.70535.

A panel of clinicians, subject-matter experts, and guideline methodologists convened by the Alzheimer’s Association conducted a systematic review and formulated evidence-based recommendations for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer’s disease (AD) within specialised care settings. The scope focuses on individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia, who are undergoing evaluation by providers trained and experienced in memory disorders, where AD is the suspected underlying aetiology.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

DIA-MHRA Global Summit

Senate House, Malet Street, London, WC1E 7HU
16-17 November, 2026

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November, 2026

UK NEQAS webinar: Epigenetics

Online
1 December, 2026

Weqas Annual POCT Conference 2026

London, Venue - TBC
8-9 December, 2026

UK NEQAS webinar: Fresh Muscle Biopsies

Online
8 December, 2026